Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Hydrochloric Acid. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 known ✓ | P00918 | 2/20 | 0.64 |
| ▸ | HTR6 known ✓ | P50406 | 3/20 | 0.58 |
| ▸ | MAOB known ✓ | P27338 | 3/20 | 0.48 |
| ▸ | HTR1A known ✓ | P08908 | 1/20 | 0.45 |
| ▸ | ADRA2A known ✓ | P08913 | 1/20 | 0.45 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.45 |
| ▸ | HTR3A known ✓ | P46098 | 1/20 | 0.45 |
| ▸ | HTR2A known ✓ | P28223 | 1/20 | 0.45 |
| ▸ | F2 | P00734 | 2/20 | 1.00 |
| ▸ | TMPRSS4 | Q9NRS4 | 2/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.96 |
| ▸ | TP53 | P04637 | 1/20 | 0.96 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.96 |
| ▸ | TSHR | P16473 | 1/20 | 0.96 |
| ▸ | CA1 | P00915 | 2/20 | 0.64 |
| ▸ | CA12 | O43570 | 1/20 | 0.64 |
| ▸ | CA4 | P22748 | 1/20 | 0.64 |
| ▸ | CA6 | P23280 | 1/20 | 0.64 |
| ▸ | CA5A | P35218 | 1/20 | 0.64 |
| ▸ | CA7 | P43166 | 1/20 | 0.64 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL6425431 | 1.00 | F2 (1.00) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| Hydrochloric Acid SCHEMBL28825226 | 0.98 | F2 (0.96) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| SCHEMBL77781 | 0.98 | F2 (1.00) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| Hydrochloric Acid SCHEMBL723369 | 0.94 | F2 (0.92) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| Hypochlorous Acid SCHEMBL17004810 | 0.92 | F2 (0.89) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| Hydrochloric Acid SCHEMBL21199324 | 0.83 | F2 (0.70) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| SCHEMBL31631413 | 0.82 | F2 (0.71) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| Hydrochloric Acid SCHEMBL2352021 | 0.81 | CA2 (0.96) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| SCHEMBL6680951 | 0.80 | HTR6 (0.84) | F2TMPRSS4CYP1A2TP53CYP2D6 | |
| Benzamidine SCHEMBL3427811 | 0.79 | F2 (0.66) | F2TMPRSS4CYP1A2TP53CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 2693 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20260125640-A1 | ACELLULAR PLACENTAL PREPARATIONS | PLAKOUS THERAPEUTICS INC (US) | 2026-05-07 | — | — | US | claimed |
| EP-4712983-A1 | AGENTS TO GENERATE REPAIR OLIGODENDROCYTES AND THEIR USE FOR AXONAL REGROWTH | Johannes Gutenberg-Universität Mainz (DE) | 2026-03-25 | — | — | EP | claimed |
| US-12584161-B2 | Stabilization of nucleic acids in urine | STRECK LLC (US) | 2026-03-24 | — | — | US | claimed |
| US-20260014232-A1 | Pharmaceutical Composition of GLP-1 and GIP Receptor Dual Agonist and Use Thereof | JIANGSU HENGRUI PHARMACEUTICALS CO LTD (CN) | 2026-01-15 | — | — | US | claimed |
| EP-4662310-A2 | METHODS AND KITS FOR LABELING CELLULAR MOLECULES FOR MULTIPLEX ANALYSIS | Parse Biosciences, Inc. (US) | 2025-12-17 | — | — | EP | claimed |
| EP-4631514-A1 | ORAL POLYPEPTIDE COMPOSITION AND USE THEREOF | Hefei Tianhui Biotech Co., Ltd. (CN) | 2025-10-15 | — | — | EP | claimed |
| US-20250281579-A1 | Methods and Compositions for Oral Administration of Proteins | ORAMED PHARMACEUTICALS INC (IL) | 2025-09-11 | — | — | US | claimed |
| EP-4008400-B1 | ACELLULAR PLACENTAL PREPARATIONS | PLAKOUS THERAPEUTICS INC (US) | 2025-06-18 | — | — | EP | claimed |
| CN-118068012-B | Human membranous nephropathy related index detection kit, method and application thereof | 杭州赛基生物科技股份有限公司 | 2025-06-17 | — | — | CN | claimed |
| CN-119968205-A | Oral polypeptide composition and application thereof | 合肥天汇生物科技有限公司 | 2025-05-09 | — | — | CN | claimed |
| US-6235509-B1 | ADDING THESE COMPOUNDS TO SAMPLE AVOIDS NONSPECIFIC DERIVATIZATION OF PROTEINS OTHER THAN SERINE PROTEASES; USED IN PROCESS FERMENTATIONS, CULTURE BROTHS AND CELL LYSATES | ROCHE DIAGNOSTICS GMBH (DE) | 2001-05-22 | — | — | US | claimed |
| EP-1074842-A1 | Catalytic anti-factor VIII allo-antibodies | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2001-02-07 | — | — | EP | claimed |
| WO-2001007918-A1 | CATALYTIC ANTI-FACTOR VIII ALLO-ANTIBODIES | INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM) (FR) | 2001-02-01 | — | — | WO | claimed |
| EP-0787014-A4 | USE OF FLEA PROTEASES AND PROTEASE INHIBITORS TO PROTECT ANIMALS FROM FLEA INFESTATION | HESKA CORP (US) | 2001-01-10 | — | — | EP | claimed |
| EP-1061963-A1 | PROTEASE INHIBITORS IN ABSORBENT ARTICLES | THE PROCTER & GAMBLE COMPANY (US) | 2000-12-27 | — | — | EP | claimed |
| US-5985273-A | AMINOPEPTIDASE INHIBITORS OR METALLOPEPTIDASE INHIBITORS AND FURTHER COMPRISE A NON-STRONGLY-CHELATING PEPTIDASE INHIBITOR. | REED BENJAMIN J (AU) | 1999-11-16 | — | — | US | claimed |
| WO-1999045974-A1 | PROTEASE INHIBITORS IN ABSORBENT ARTICLES | THE PROCTER & GAMBLE COMPANY (US) | 1999-09-16 | — | — | WO | claimed |
| US-5695928-A | CONCURRENT EXTRACTION, COMPLEXING | NOVARTIS CORPORATION | 1997-12-09 | — | — | US | claimed |
| EP-0787014-A1 | USE OF FLEA PROTEASES AND PROTEASE INHIBITORS TO PROTECT ANIMALS FROM FLEA INFESTATION | Heska Corporation (US) | 1997-08-06 | — | — | EP | claimed |
| WO-1996011706-A1 | USE OF FLEA PROTEASES AND PROTEASE INHIBITORS TO PROTECT ANIMALS FROM FLEA INFESTATION | HESKA CORPORATION (US) | 1996-04-25 | — | — | WO | claimed |